Axsome Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It is also developing AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics Inc.

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics today and set a price target of $310.00. Suvannavejh cov...

Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Morgan Stanley analyst Sean Laaman maintained a Hold rating on Axsome Therapeutics today and set a price target of $242.00. According to TipRanks, ...

Morgan Stanley Sticks to Its Hold Rating for Axsome Therapeutics (AXSM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Travere Therapeutics (TVTX) and Axsome Therapeutics ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Axsome Therapeutics Inc. (($AXSM)) has held its Q1 earnings call. Read on for the main highlights of the call. Axsome Therapeutics Inc. struck an u...

Axsome Therapeutics Earnings Call Signals Aggressive Growth

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evotec AG (EVO), Twist Bioscience (TWST) and Axsome ...

Analysts Offer Insights on Healthcare Companies: Evotec AG (EVO), Twist Bioscience (TWST) and Axsome Therapeutics (AXSM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arvinas Holding Company (ARVN) and Axsome Therapeuti...

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Axsome Therapeutics (AXSM)

Axsome Therapeutics ( ($AXSM) ) just unveiled an update. On May 4, 2026, Axsome Therapeutics reported first quarter 2026 net product revenue of $19...

Axsome Highlights Strong Q1 Growth and AUVELITY Expansion

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics (AXSM) and Kymera Therapeutics (...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Evommune, Inc. (EVMN) an...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Evommune, Inc. (EVMN) and Alnylam Pharma (ALNY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incy...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AXSM	$234.20	-0.75%	600.51K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AXSM	$234.20	-0.8%	600.51K
3
4
5
6

AXSM

AXSM

Get Axsome Therapeutics Inc. Data in Excel

Get Axsome Therapeutics Inc. Data in Excel